AlphaCentric Advisors LLC Sells 8,250 Shares of United Therapeutics Co. (NASDAQ:UTHR)

AlphaCentric Advisors LLC lowered its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,250 shares of the biotechnology company's stock after selling 8,250 shares during the quarter. United Therapeutics accounts for 1.7% of AlphaCentric Advisors LLC's portfolio, making the stock its 14th biggest position. AlphaCentric Advisors LLC's holdings in United Therapeutics were worth $2,240,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. LSV Asset Management grew its holdings in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after acquiring an additional 436,851 shares during the last quarter. Swedbank AB bought a new stake in shares of United Therapeutics in the first quarter worth about $97,316,000. Canada Pension Plan Investment Board raised its position in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock valued at $41,533,000 after purchasing an additional 153,700 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after buying an additional 92,240 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of United Therapeutics by 49.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock worth $88,089,000 after buying an additional 91,597 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 25,000 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Michael Benkowitz sold 25,000 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $833,350.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christopher Causey sold 510 shares of the firm's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company's stock, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,022 shares of company stock valued at $38,496,532 in the last quarter. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Up 1.6 %

NASDAQ:UTHR traded up $6.07 on Tuesday, reaching $382.87. 217,535 shares of the company's stock traded hands, compared to its average volume of 464,848. The stock has a 50-day simple moving average of $356.00 and a 200-day simple moving average of $318.81. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $382.90. The firm has a market cap of $17.09 billion, a PE ratio of 16.63, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.38 earnings per share. On average, equities analysts anticipate that United Therapeutics Co. will post 25.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on UTHR. HC Wainwright raised their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. UBS Group increased their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a "buy" rating in a research note on Monday, July 8th. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, Morgan Stanley lowered United Therapeutics from an "overweight" rating to an "equal weight" rating and increased their target price for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.